vs
Side-by-side financial comparison of Celanese Corp (CE) and Dexcom (DXCM). Click either name above to swap in a different company.
Celanese Corp is the larger business by last-quarter revenue ($2.2B vs $1.3B, roughly 1.7× Dexcom). Dexcom runs the higher net margin — 21.2% vs 0.6%, a 20.6% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs -7.0%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs -8.1%).
Celanese Corporation, formerly known as Hoechst Celanese, is an American technology and specialty materials company headquartered in Irving, Texas. It is a Fortune 500 corporation. The company is the world's leading producer of acetic acid, producing about 1.95 million tonnes per year, representing approximately 20% of global production. Celanese is also the world's largest producer of vinyl acetate monomer (VAM).
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
CE vs DXCM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.2B | $1.3B |
| Net Profit | $14.0M | $267.3M |
| Gross Margin | 19.1% | 62.9% |
| Operating Margin | 4.0% | 25.6% |
| Net Margin | 0.6% | 21.2% |
| Revenue YoY | -7.0% | 21.6% |
| Net Profit YoY | 100.7% | 153.6% |
| EPS (diluted) | $0.13 | $0.67 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.3B | ||
| Q4 25 | $2.2B | $1.3B | ||
| Q3 25 | $2.4B | $1.2B | ||
| Q2 25 | $2.5B | $1.2B | ||
| Q1 25 | $2.4B | $1.0B | ||
| Q4 24 | $2.4B | $1.1B | ||
| Q3 24 | $2.6B | $994.2M | ||
| Q2 24 | $2.7B | $1.0B |
| Q1 26 | — | $267.3M | ||
| Q4 25 | $14.0M | $267.3M | ||
| Q3 25 | $-1.4B | $283.8M | ||
| Q2 25 | $199.0M | $179.8M | ||
| Q1 25 | $-21.0M | $105.4M | ||
| Q4 24 | $-1.9B | $151.7M | ||
| Q3 24 | $116.0M | $134.6M | ||
| Q2 24 | $155.0M | $143.5M |
| Q1 26 | — | 62.9% | ||
| Q4 25 | 19.1% | 62.9% | ||
| Q3 25 | 21.5% | 60.5% | ||
| Q2 25 | 21.1% | 59.5% | ||
| Q1 25 | 19.9% | 56.9% | ||
| Q4 24 | 22.7% | 58.9% | ||
| Q3 24 | 23.5% | 59.7% | ||
| Q2 24 | 24.2% | 62.4% |
| Q1 26 | — | 25.6% | ||
| Q4 25 | 4.0% | 25.6% | ||
| Q3 25 | -52.7% | 20.1% | ||
| Q2 25 | 9.2% | 18.4% | ||
| Q1 25 | 7.0% | 12.9% | ||
| Q4 24 | -59.3% | 17.0% | ||
| Q3 24 | 9.4% | 15.3% | ||
| Q2 24 | 9.4% | 15.7% |
| Q1 26 | — | 21.2% | ||
| Q4 25 | 0.6% | 21.2% | ||
| Q3 25 | -56.1% | 23.5% | ||
| Q2 25 | 7.9% | 15.5% | ||
| Q1 25 | -0.9% | 10.2% | ||
| Q4 24 | -80.8% | 13.6% | ||
| Q3 24 | 4.4% | 13.5% | ||
| Q2 24 | 5.8% | 14.3% |
| Q1 26 | — | $0.67 | ||
| Q4 25 | $0.13 | $0.67 | ||
| Q3 25 | $-12.39 | $0.70 | ||
| Q2 25 | $1.81 | $0.45 | ||
| Q1 25 | $-0.19 | $0.27 | ||
| Q4 24 | $-17.50 | $0.37 | ||
| Q3 24 | $1.06 | $0.34 | ||
| Q2 24 | $1.41 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $917.7M |
| Total DebtLower is stronger | $11.4B | — |
| Stockholders' EquityBook value | $4.0B | $2.7B |
| Total Assets | $21.7B | $6.3B |
| Debt / EquityLower = less leverage | 2.81× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $917.7M | ||
| Q4 25 | — | $917.7M | ||
| Q3 25 | — | $1.8B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $904.9M | ||
| Q4 24 | — | $606.1M | ||
| Q3 24 | — | $621.2M | ||
| Q2 24 | — | $939.2M |
| Q1 26 | — | — | ||
| Q4 25 | $11.4B | — | ||
| Q3 25 | $11.7B | — | ||
| Q2 25 | $12.7B | — | ||
| Q1 25 | $12.4B | — | ||
| Q4 24 | $11.1B | — | ||
| Q3 24 | $11.3B | — | ||
| Q2 24 | $11.1B | — |
| Q1 26 | — | $2.7B | ||
| Q4 25 | $4.0B | $2.7B | ||
| Q3 25 | $4.0B | $2.7B | ||
| Q2 25 | $5.3B | $2.6B | ||
| Q1 25 | $5.2B | $2.3B | ||
| Q4 24 | $5.2B | $2.1B | ||
| Q3 24 | $7.3B | $2.0B | ||
| Q2 24 | $7.2B | $2.4B |
| Q1 26 | — | $6.3B | ||
| Q4 25 | $21.7B | $6.3B | ||
| Q3 25 | $22.2B | $7.5B | ||
| Q2 25 | $23.7B | $7.3B | ||
| Q1 25 | $23.2B | $6.8B | ||
| Q4 24 | $22.9B | $6.5B | ||
| Q3 24 | $25.9B | $6.4B | ||
| Q2 24 | $25.8B | $6.8B |
| Q1 26 | — | — | ||
| Q4 25 | 2.81× | — | ||
| Q3 25 | 2.95× | — | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.14× | — | ||
| Q3 24 | 1.56× | — | ||
| Q2 24 | 1.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $252.0M | — |
| Free Cash FlowOCF − Capex | $168.0M | — |
| FCF MarginFCF / Revenue | 7.6% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | 18.00× | — |
| TTM Free Cash FlowTrailing 4 quarters | $803.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $252.0M | $294.0M | ||
| Q3 25 | $447.0M | $659.9M | ||
| Q2 25 | $410.0M | $303.0M | ||
| Q1 25 | $37.0M | $183.8M | ||
| Q4 24 | $494.0M | $301.4M | ||
| Q3 24 | $79.0M | $199.5M | ||
| Q2 24 | $292.0M | $279.4M |
| Q1 26 | — | — | ||
| Q4 25 | $168.0M | $192.1M | ||
| Q3 25 | $383.0M | $579.4M | ||
| Q2 25 | $317.0M | $208.9M | ||
| Q1 25 | $-65.0M | $96.8M | ||
| Q4 24 | $389.0M | $176.8M | ||
| Q3 24 | $-9.0M | $88.3M | ||
| Q2 24 | $187.0M | $213.3M |
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 15.3% | ||
| Q3 25 | 15.8% | 47.9% | ||
| Q2 25 | 12.5% | 18.1% | ||
| Q1 25 | -2.7% | 9.3% | ||
| Q4 24 | 16.4% | 15.9% | ||
| Q3 24 | -0.3% | 8.9% | ||
| Q2 24 | 7.1% | 21.2% |
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 8.1% | ||
| Q3 25 | 2.6% | 6.7% | ||
| Q2 25 | 3.7% | 8.1% | ||
| Q1 25 | 4.3% | 8.4% | ||
| Q4 24 | 4.4% | 11.2% | ||
| Q3 24 | 3.3% | 11.2% | ||
| Q2 24 | 4.0% | 6.6% |
| Q1 26 | — | — | ||
| Q4 25 | 18.00× | 1.10× | ||
| Q3 25 | — | 2.33× | ||
| Q2 25 | 2.06× | 1.69× | ||
| Q1 25 | — | 1.74× | ||
| Q4 24 | — | 1.99× | ||
| Q3 24 | 0.68× | 1.48× | ||
| Q2 24 | 1.88× | 1.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CE
| Engineered Materials | $1.3B | 58% |
| Acetyl Chain | $940.0M | 43% |
DXCM
Segment breakdown not available.
